Design and analysis of a 3‐arm noninferiority trial with a prespecified margin for the hazard ratio. (9th July 2018)

• Record Type: Journal Article
• Authors: Hida, Eisuke; Tango, Toshiro
• Is Part Of: Pharmaceutical statistics. Volume 17:Number 5(2018)
• Page Start: 489
• Page End: 503
• Publication Date: 2018-07-09
• Subjects: assay sensitivity -- log‐rank test -- noninferiority margin -- time‐to‐event -- optimal allocation -- 3‐arm noninferiority; Pharmacy -- Statistical methods -- Periodicals; Pharmacy -- Statistics -- Periodicals; 615.10727
• DOI: 10.1002/pst.1875
• Languages: English
• ISSNs: 1539-1604

Abstract

Abstract : A 3‐arm trial design that includes an experimental treatment, an active reference treatment, and a placebo is useful for assessing the noninferiority of an experimental treatment. The inclusion of a placebo arm enables the assessment of assay sensitivity and internal validation, in addition to the testing of the noninferiority of the experimental treatment compared with the reference treatment. In 3‐arm noninferiority trials, various statistical test procedures have been considered to evaluate the following 3 hypotheses: (i) superiority of the experimental treatment over the placebo, (ii) superiority of the reference treatment over the placebo, and (iii) noninferiority of the experimental treatment compared with the reference treatment. However, hypothesis (ii) can be insufficient and may not accurately assess the assay sensitivity for the noninferiority of the experimental treatment compared with the reference treatment. Thus, demonstrating that the superiority of the reference treatment over the placebo is greater than the noninferiority margin (the nonsuperiority of the reference treatment compared with the placebo) can be necessary. Here, we propose log‐rank statistical procedures for evaluating data obtained from 3‐arm noninferiority trials to assess assay sensitivity with a prespecified margin Δ. In addition, we derive the approximate sample size and optimal allocation required to minimize the total sample size and that of the placebo treatment sample size, hierarchically.